Modulating inflammation for cancer therapy

Ritter, Barbara; Greten, Florian R.

doi:10.1084/jem.20181739

Cited by 126 publications

(88 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bars were showed as box and whisker graphs; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 by two-way ANOVA with Tukey's multiple comparison test. system to act effectively against metastatic tumors [67][68][69] . On this basis, the beneficial effects by checkpoint inhibitors depend on the presence of a pro-inflammatory "hot" environment 70 .…”

Section: Discussionmentioning

confidence: 99%

Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens

et al. 2020

View full text Add to dashboard Cite

Here, we developed an unbiased, functional target-discovery platform to identify immunogenic proteins from primary non-small cell lung cancer (NSCLC) cells that had been induced to apoptosis by cisplatin (CDDP) treatment in vitro, as compared with their live counterparts. Among the multitude of proteins identified, some of them were represented as fragmented proteins in apoptotic tumor cells, and acted as non-mutated neoantigens (NM-neoAgs). Indeed, only the fragmented proteins elicited effective multi-specific CD4 + and CD8 + T cell responses, upon a chemotherapy protocol including CDDP. Importantly, these responses further increased upon anti-PD-1 therapy, and correlated with patients' survival and decreased PD-1 expression. Cross-presentation assays showed that NM-neoAgs were unveiled in apoptotic tumor cells as the result of caspase-dependent proteolytic activity of cellular proteins. Our study demonstrates that apoptotic tumor cells generate a repertoire of immunogenic NM-neoAgs that could be potentially used for developing effective T cell-based immunotherapy across multiple cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Tumor-associated immune cells and their crosstalk with cancer and the components of its microenvironment dramatically affect tumor behavior and patient outcome [1,2]. The concept of cancer immunoediting, represents the dynamic of this interaction, which runs through the phases of elimination, equilibrium and escape, and explains how immunosuppression can overwhelm immunosurveillance [3], eliciting the development of immunological-based approaches to cancer treatment [4,5].…”

Section: Introductionmentioning

confidence: 99%

“…Histopathological analysis of experimental and clinical tumors has revealed that, although there is great variability, according to the tumor type and clinical-pathological profile of each patient [5,6], virtually all types of immune cells, including different subsets of T and B lymphocytes, NK and innate lymphoid cells can be part of the tumor microenvironment (TME). However, myeloid cells are the most widely represented, since they might account for up to 50% of the neoplastic mass [6,7].…”

Section: Introductionmentioning

confidence: 99%

Decoding the Role of Interleukin-30 in the Crosstalk between Cancer and Myeloid Cells

Carlo

2020

Cells

View full text Add to dashboard Cite

In the last few years, a new actor hit the scene of the tumor microenvironment, the p28 subunit of interleukin (IL)-27, known as IL-30. Its molecular structure allows it to function as an autonomous cytokine and, alternatively, to pair with other subunits to form heterodimeric complexes and enables it to play different, and not fully elucidated, roles in immunity. However, data from the experimental models and clinical samples, suggest IL-30 s engagement in the relationship between cancer and myeloid cells, which fosters the tumor microenvironment and the cancer stem cell niche, boosting the disease progression. Activated myeloid cells are the primary cellular source and one of the targets of IL-30, which can also be produced by cancer cells, especially, in aggressive tumors, as observed in the breast and prostate. This review briefly reports on the immunobiology of IL-30 and related cytokines, by comparing mouse and human counterparts, and then focuses on the mechanisms whereby IL-30 amplifies intratumoral myeloid cell infiltrate and triggers a vicious cycle that worsens immunosuppression in the tumor microenvironment (TME) and constitutes a real threat for a successful immunotherapeutic strategy.Cells 2020, 9, 615 2 of 14 of reactive oxygen species (ROS), nitric oxide (NO), and ectoenzymes, which regulate the adenosine metabolism; expression of immune checkpoint molecules [10,11]; depletion of metabolites critical for lymphocyte functions [12,13]; and through their secretion of growth, angio-lymph-angiogenic factors and inflammatory mediators [13], that are crucial for tissue remodeling and tumor development.Recent insights into this inflammatory milieu, specifically in breast (BC) and prostate (PC) cancers, have unveiled a role for the novel immunoregulatory mediator Interleukin(IL)-30/IL-27p28 [14] in the TME and in the intricate relationship between cancer and myeloid cells, which orchestrates tumor-promoting events with evident clinical implications [15,16].

show abstract

“…However, provision of antioxidants actually increases cancer risk (Jenkins et al, ), and the exact role of oxidative stress (now called redox code; Jones & Sies, ; and never fully elucidated in humans) in cancer aetiology is, to date, still elusive. Conceivably, modulation of the redox code by (poly)phenols (including OOPC) might play some roles in cancer and progression of cancer stem cells, as well as adjunct therapy (Ritter & Greten, ). Such actions are probably not mediated by direct antioxidant activities.…”

Section: Pharmacological and Nutraceutical Properties Of Htmentioning

confidence: 99%

An overview of the pharmacology of olive oil and its active ingredients

Visioli

Dávalos

Hazas

et al. 2019

British J Pharmacology

View full text Add to dashboard Cite

In addition to providing sensory stimuli, usually taste, smell and sight, olive oil contains a range of minor components, mostly phenolic in nature. These components are endowed with pharmacological or pharma‐nutritional properties that are the subject of active research worldwide. Based on our more than 25 years of experience in this field, we critically focus on what we believe are the most pharmacologically prominent actions of the constituents of olive oil. Most of the effects are due to the phenolic compounds in extra virgin olive oil, such as hydroxytyrosol and oleocanthal (which are often mis‐categorized as in vivo antioxidants) and concern the cardiovascular system. Other potentially beneficial activities are still to be investigated in depth. We conclude that—in the context of a proper diet that includes high‐quality products—the use of high‐quality olive oil contributes to achieving and sustaining overall health. Linked Articles This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc

show abstract

Modulating inflammation for cancer therapy

Abstract: This review provides a concise overview of pro- and anti-inflammatory approaches in current tumor therapy.

Cited by 126 publications

References 129 publications

Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens

Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens

Decoding the Role of Interleukin-30 in the Crosstalk between Cancer and Myeloid Cells

An overview of the pharmacology of olive oil and its active ingredients

Contact Info

Product

Resources

About